What are aromatase inhibitors and tamoxifen?
Aromatase inhibitors and tamoxifen are hormone (endocrine) therapies used mainly for breast cancer that grows in response to the hormone oestrogen. About three in four breast cancers have oestrogen receptors (they are “ER-positive” or “hormone receptor-positive”). These cancers use oestrogen as a growth signal, so blocking that signal can stop them growing.
The two types of medicine work in different ways:
| Medicine | How it works | Examples |
|---|---|---|
| Tamoxifen | Blocks oestrogen from attaching to its receptor on breast cancer cells | Tamoxifen |
| Aromatase inhibitors (AIs) | Lower the amount of oestrogen the body makes after the menopause | Anastrozole, letrozole, exemestane |
Both are taken as a daily tablet, usually for 5-10 years after surgery for early breast cancer. They lower the chance of the cancer coming back and of a new cancer developing in the other breast. They are also used to control breast cancer that has spread, and sometimes to prevent breast cancer in women at high risk.
A brief history
Tamoxifen was first developed in the 1960s, oddly enough as a possible contraceptive. It became a breast cancer treatment in the 1970s and is now one of the most widely used cancer medicines in the world. Aromatase inhibitors arrived in the 1990s and were soon shown to work even better than tamoxifen for many postmenopausal women.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Hormone therapy |
| Main use | Hormone receptor-positive breast cancer in women and men |
| How it is given | Tablet once a day |
| Course length | Usually 5 years, sometimes up to 10 years |
| Who gets AIs | Mainly postmenopausal women, or premenopausal women with ovarian suppression |
| Who gets tamoxifen | Premenopausal and postmenopausal women, and men |
| Common side effects | Hot flushes, joint pain (AIs), vaginal dryness, mood changes |
| Serious risks | Bone thinning (AIs); blood clots and womb cancer (tamoxifen, rare) |
2. How it works
Where oestrogen comes from
| Life stage | Main source of oestrogen |
|---|---|
| Before the menopause | The ovaries |
| After the menopause | Fat, muscle and other tissues, where the enzyme aromatase converts other hormones into oestrogen |
| Men | Mostly made by aromatase from testosterone |
Tamoxifen
Tamoxifen is a selective oestrogen receptor modulator (SERM). In breast tissue, it sits in the oestrogen receptor and blocks it, like a key that fits a lock but does not turn. In some other tissues, such as bone and the lining of the womb, it acts partly like oestrogen. This explains both some benefits, such as helping protect bones after the menopause, and some risks, such as a small increase in womb cancer.
Aromatase inhibitors
AIs block the aromatase enzyme and lower oestrogen levels throughout the body. They work well after the menopause, when the ovaries have stopped producing oestrogen. Before the menopause, the ovaries would simply make more oestrogen, so AIs are only used in younger women together with ovarian suppression (injections or surgery that switch off the ovaries).
3. Who it is for
Conditions treated
| Condition | Role |
|---|---|
| Invasive ductal carcinoma | Standard for hormone receptor-positive cancers after surgery, and for advanced disease |
| Invasive lobular carcinoma | Almost always hormone receptor-positive; endocrine therapy is central |
| Tubular carcinoma of the breast | Usually hormone receptor-positive with an excellent outlook |
| Mucinous carcinoma of the breast | Often hormone receptor-positive |
| Ductal carcinoma in situ | Sometimes used after surgery to lower the risk of new breast cancer |
| Lobular carcinoma in situ | Can be used to lower future breast cancer risk |
| Male breast cancer | Tamoxifen is the usual first choice |
| Low-grade serous ovarian carcinoma | Letrozole and other hormone treatments are used |
| Ovarian granulosa cell tumour | AIs are sometimes used for recurrent disease |
Choosing between them
| Situation | Usual choice |
|---|---|
| Postmenopausal women | An AI, or tamoxifen followed by an AI |
| Premenopausal women, lower risk | Tamoxifen |
| Premenopausal women, higher risk | Ovarian suppression plus an AI or tamoxifen |
| Men | Tamoxifen; an AI with testosterone suppression if tamoxifen is unsuitable |
| History of blood clots | AI usually preferred |
| Osteoporosis | Tamoxifen may be preferred, or an AI with bone protection |
4. Before treatment
| Step | Why it is done |
|---|---|
| Confirm hormone receptor status | Treatment only helps hormone receptor-positive cancers |
| Menopausal status | Decides which drug can be used |
| Bone density scan | Recommended before starting an AI |
| Medicines review | Some antidepressants can reduce the effect of tamoxifen |
| Clot risk assessment | Before tamoxifen |
| Contraception plan | Tamoxifen can harm an unborn baby |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Starting | Usually after surgery, and after chemotherapy or radiotherapy if these are given |
| 2. Daily tablet | Take it at the same time each day, with or without food |
| 3. First review | Usually after 2-3 months to check side effects |
| 4. Regular follow-up | Every 6-12 months, with mammograms each year |
| 5. Possible switch | Some women change from tamoxifen to an AI after 2-3 years, or the other way round |
| 6. Decision at 5 years | Your team discusses whether to stop or continue for longer |
Set a daily reminder on your phone or keep tablets next to something you use every morning.
Ovarian suppression
For premenopausal women who need ovarian suppression, this is usually given as a monthly or three-monthly injection of goserelin or a similar drug. Some women choose surgery to remove the ovaries instead.
Sticking with treatment
Many women find it hard to keep taking a daily tablet for years, especially if side effects are troublesome. Stopping early increases the risk of the cancer returning. If side effects are a problem, talk to your team: switching to a different drug, short breaks or treatments for side effects often help.
6. Side effects and risks
| Side effect | Tamoxifen | Aromatase inhibitors |
|---|---|---|
| Hot flushes and night sweats | Common | Common |
| Joint and muscle pain | Less common | Common, sometimes severe |
| Vaginal dryness | Less common | Common |
| Vaginal discharge or bleeding | Common; report any bleeding after the menopause | Uncommon |
| Bone thinning | Protective after the menopause | Increased risk |
| Blood clots | Increased risk | Little or no increase |
| Womb (endometrial) cancer | Small increased risk after the menopause | No increase |
| Mood changes | Possible | Possible |
| Hair thinning | Occasional | Occasional |
| Raised cholesterol | Uncommon | Possible |
Numbers from ATLAS
In the ATLAS trial, women who took tamoxifen for a full decade had a higher risk of blood clots in the lung and of womb cancer. The cumulative risk of womb cancer over years 5-14 was about 3.1% with 10 years of tamoxifen compared with 1.6% in women who stopped at 5 years (Davies et al., 2013).
7. Results and outlook
| Study | Main finding |
|---|---|
| EBCTCG meta-analysis, about 32,000 postmenopausal women | Five years of an AI lowered recurrence compared with five years of tamoxifen, and 10-year breast cancer mortality was 12.1% versus 14.2% (EBCTCG, 2015) |
| ATLAS, about 6,800 women with ER-positive cancer | Taking tamoxifen for a decade rather than half that time lowered the chance of recurrence and breast cancer death, with most of the benefit seen after year 10 (Davies et al., 2013) |
| SOFT and TEXT, premenopausal women | Adding ovarian suppression to tamoxifen improved 8-year survival, and exemestane plus ovarian suppression gave the lowest recurrence rates, at the cost of more side effects (Francis et al., 2018) |
How long to continue
Five years of endocrine therapy is the standard starting point. For women with a higher chance of recurrence, such as those whose cancer had spread to lymph nodes, continuing for 7-10 years may give extra protection. The decision balances the extra benefit against the side effects of longer treatment, and is made together with your team.
A long-lasting benefit
Endocrine therapy for early breast cancer has a “carry-over” effect: its benefit continues for years after the tablets are stopped. This is one reason why women are encouraged to complete the full course.
8. Recovery and aftercare
Managing common side effects
| Side effect | What can help |
|---|---|
| Hot flushes | Layered clothing, fans, avoiding triggers; some non-hormonal medicines can help |
| Joint pain | Regular exercise, simple painkillers, switching to another AI |
| Vaginal dryness | Non-hormonal moisturisers and lubricants; ask about low-dose vaginal oestrogen |
| Bone thinning | Weight-bearing exercise, calcium, vitamin D and bone-strengthening drugs |
| Low mood | Talking therapies and support groups |
| Weight gain | Balanced diet and regular activity |
Emotional wellbeing
Taking a daily tablet can be a constant reminder of cancer, long after other treatment has ended. Some women feel anxious about recurrence; others feel frustrated by side effects that affect work, sleep or relationships. Support groups, counselling and open conversations with your breast care nurse can help you find a way to live well during these years.
Warning signs to report
- Leg swelling, pain or redness, or sudden breathlessness (possible blood clot, mainly with tamoxifen)
- Vaginal bleeding after the menopause while on tamoxifen
- New lumps, bone pain or persistent cough
- Severe joint pain that stops you from doing daily activities
Follow-up
| Check | Typical timing |
|---|---|
| Clinic review | Every 6-12 months |
| Mammogram | Every year |
| Bone density scan | Every 1-2 years on an AI |
| Cholesterol | Periodically on an AI |
Pregnancy and fertility
Tamoxifen can harm a developing baby, so reliable non-hormonal contraception is needed during treatment and for a few months afterwards. Women who want to become pregnant may be able to pause treatment under specialist guidance; discuss this with your team before stopping.
Prevention in women at high risk
Some women who have never had breast cancer but have a high risk, for example because of a strong family history or a previous diagnosis of lobular carcinoma in situ, may be offered tamoxifen or an aromatase inhibitor to lower their risk. This is called chemoprevention. Treatment usually lasts 5 years, and the decision depends on the balance between expected benefit and side effects.
Combining with other treatments
For some higher-risk early breast cancers, a CDK4/6 inhibitor tablet, such as abemaciclib or ribociclib, is added to hormone therapy for the first few years. In advanced breast cancer, hormone therapy is commonly combined with these drugs as first treatment.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Ovarian suppression alone | Rarely used alone |
| Fulvestrant | Advanced breast cancer; an injection that breaks down the oestrogen receptor |
| CDK4/6 inhibitors | Added to hormone therapy for advanced cancer and for some higher-risk early cancers |
| Oral SERDs | Newer oestrogen receptor blockers for advanced cancer, especially with ESR1 mutations |
| Chemotherapy | For higher-risk cancers, in addition to hormone therapy |
| Prevention options | Tamoxifen, raloxifene or an AI for women at high risk |
If cancer returns or spreads while on one hormone treatment, switching to another, often combined with a targeted drug, can still be effective.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Will I lose my hair? | Usually not, although some thinning can occur |
| Can I take HRT? | Usually not, as it may feed the cancer |
| Do I need to take it for 10 years? | It depends on your risk; your team will discuss this |
| Can men take these drugs? | Yes; tamoxifen is often used for male breast cancer |
| Does grapefruit interact? | Ask your pharmacist; it depends on the medicine |
| Can I drink alcohol? | Small amounts are usually fine |
| What if I miss a dose? | Take the next dose as normal; do not double up |
11. Questions to ask your care team
- Should I take tamoxifen or an aromatase inhibitor, and why?
- Do I need ovarian suppression?
- How long should I take treatment?
- What can I do about side effects?
- Do I need a bone density scan?
- Will any of my other medicines interact?
- What should I do if I want to become pregnant?
Resources
- Davies, C. et al. (2013) ‘Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial’, The Lancet, 381(9869), pp. 805-816.
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) ‘Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials’, The Lancet, 386(10001), pp. 1341-1352.
- Francis, P.A. et al. (2018) ‘Tailoring adjuvant endocrine therapy for premenopausal breast cancer’, New England Journal of Medicine, 379(2), pp. 122-137.
- National Cancer Institute (2026) Hormone Therapy – Breast Cancer Treatment. Available at: https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet (Accessed: October 2026).
- National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.